Drug Profile
Research programme: hepatitis B therapeutics - Chromis Therapeutics
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Chromis Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 31 Aug 2023 Preclinical development is ongoing in Hepatitis-B in USA (PO) (Chromis Therapeutics pipeline; August 2023)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)
- 25 Feb 2016 Preclinical development in Hepatitis B in USA (PO)